60 Degrees Pharmaceuticals, Inc. (SXTP)

USD 1.38

(-6.76%)

Market Cap (In USD)

3.17 Million

Revenue (In USD)

253.57 Thousand

Net Income (In USD)

-3.76 Million

Avg. Volume

742.83 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.702-18.36
PE
-
EPS
-
Beta Value
5.2708673
ISIN
US83006G1040
CUSIP
83006G104
CIK
1946563
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Geoffrey Stuart Dow
Employee Count
-
Website
https://60degreespharma.com
Ipo Date
2023-07-12
Details
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.